November 23, 2016 - By Nellie Frank
Ganesh Kaundinya who is the acting Senior V.P. – Research of Momenta Pharmaceuticals Inc recently sold 1,048 shares of the stock exchange listed company. The insider sale has $14,311 US Dollars total value, at an average price per share of $13.7. Ganesh Kaundinya owns 0.65% of the -company’s market cap or 454,015 shares. A Form 4 freely accessible here disclosed this trade activity. It was disclosed on November 23, 2016 and filled with U.S. SEC.
Out of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 56% are positive. $31 is the highest target while $6 is the lowest. The $17.11 average target is 25.81% above today’s ($13.6) stock price. Momenta Pharmaceuticals has been the topic of 17 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating given on Tuesday, November 22 by Aegis Capital. The firm earned “Equal-Weight” rating on Monday, November 23 by Barclays Capital. The firm has “Overweight” rating by JP Morgan given on Friday, November 13. The company was upgraded on Tuesday, October 11 by Barclays Capital. The rating was maintained by Leerink Swann on Wednesday, May 4 with “Outperform”. Maxim Group downgraded the shares of MNTA in a report on Wednesday, September 7 to “Sell” rating. Goldman Sachs initiated Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Monday, June 6 with “Neutral” rating. The firm earned “Neutral” rating on Thursday, August 6 by Goldman Sachs. On Tuesday, October 13 the stock rating was maintained by Leerink Swann with “Outperform”. Maxim Group upgraded the shares of MNTA in a report on Friday, January 8 to “Hold” rating.
Insitutional Activity: The institutional sentiment decreased to 1.35 in 2016 Q2. Its down 0.03, from 1.38 in 2016Q1. The ratio worsened, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
The New York-based Morgan Stanley has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). North Run Capital Limited Partnership holds 1.4% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 787,500 shares. Numeric Lc accumulated 0.05% or 536,730 shares. National Bank & Trust Of Montreal Can reported 1,755 shares or 0% of all its holdings. Palo Alto Investors Ltd Liability owns 1.63M shares or 1.33% of their US portfolio. The California-based Wells Fargo & Mn has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Architects Inc reported 132 shares or 0% of all its holdings. Teachers Advisors has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Ls Advsrs holds 2,648 shares or 0% of its portfolio. Sei Invests has 7 shares for 0% of their US portfolio. Los Angeles Management And Equity Research holds 0% or 32,105 shares in its portfolio. Pacad Inv Ltd has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Moreover, Laurion Cap Mgmt L P has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 18,000 shares. Sectoral Asset Mngmt holds 574,040 shares or 0.64% of its portfolio.
Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 6 insider sales for $188,231 net activity. Shares for $67,600 were sold by Shapiro Bennett M. 972 Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares with value of $11,717 were sold by Shea Richard P. WHEELER CRAIG A sold $70,704 worth of stock. Leicher Bruce sold $12,415 worth of stock. $13,151 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Roach James M. Another trade for 1,049 shares valued at $12,644 was sold by Kaundinya Ganesh Venkataraman.
About 124,523 shares traded hands. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 37.98% since April 21, 2016 and is uptrending. It has outperformed by 32.65% the S&P500.
Momenta Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $901.06 million. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It currently has negative earnings. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics.
According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”
Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on February, 16. They expect $-0.21 earnings per share, up 51.16% or $0.22 from last year’s $-0.43 per share. After $-0.26 actual earnings per share reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23% EPS growth.
More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales” on November 04, 2016, also Fool.com with their article: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” published on October 11, 2016, Fool.com published: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” on March 04, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” published on August 09, 2016 as well as Fool.com‘s news article titled: “Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today” with publication date: February 18, 2016.
Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank